Researchers have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated non-small cell lung cancer following treatment with the ...

This study concludes that sotorasib resistance can arise through the activation of alternative signaling pathways, underscoring the adaptability of biological networks in cancer cells. However, this ...

In the phase III CodeBreaK 300 study, sotorasib 960 mg-panitumumab significantly prolonged progression-free survival (PFS) versus investigator's choice (trifluridine/tipiracil or regorafenib) in ...

In the CodeBreaK 300 trial, sotorasib and panitumumab had better response rates and improved PFS than standard-of-care treatment options.

Vectibix ® in combination with sotorasib, is indicated for the treatment of adult patients with KRAS G12C -mutated mCRC, as determined by an FDA-approved test, who have received prior treatment ...

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) for the treatment of adult ...

The authors hypothesized that since sotorasib has shown some efficacy in patients with NSCLC, it could also be an option for patients with vascular malformations found to have the KRAS G12C mutation.

Investigators compared cost-effectiveness of the KRAS inhibitor sotorasib against the taxane docetaxel in the second line for non–small cell lung cancer (NSCLC).

Conclusions: Sotorasib in combination with CBDCA/PEM demonstrated favorable ORR with modest PFS and good tolerability in advanced non-Sq, NSCLC patients with KRAS G12C mutation. Clinical trial ...